EUVIMEDEUVIMED entdecken
Crossref

2837-LB: Pharmacokinetic and Safety Evaluation of AUL009, a Monthly Semaglutide-Loaded Microsphere Injectables Utilizing ExTenna Drug Delivery Technology in Healthy Male Subjects

SEOA KIM, CHERNGJU KIM, TAEKUN AN, ARAM KIM, JIWON PARK

Diabetes · 05.06.2026 · 75 (Supplement_1)

DOI: 10.2337/db26-2837-lb ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von SEOA KIM und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is widely used for the treatment of type 2 diabetes and obesity. However, once-weekly formulations may present adherent challenges and gastrointestinal adverse events related to peak plasma exposure. AUL009 is a semaglutide-loaded microsphere monthly injectables developed using ExTenna™ drug delivery technology to enable sustained drug release and reduce peak-related effects. This study evaluated the pharmacokinetics and safety of AUL009 in healthy male subjects.

Methods

In this randomized study, twelve healthy male subjects received a single subcutaneous injection of either AUL009 (4 mg semaglutide) or once-weekly semaglutide (Wegovy® 1 mg). Plasma concentrations were measured for 56 days in the AUL009 group and 28 days in the reference group. Pharmacokinetic parameters were estimated using non-compartmental analysis (Phoenix® WinNonlin® v8.4).

Results

Mean age and BMI were 43.1 ± 14.1 years and 23.6 ± 3.3 kg/m² in the AUL009 group and 51.7 ± 12.4 years and 24.5 ± 3.0 kg/m² in the reference group. AUL009 showed a lower Cmax (36.75 vs. 92.44 ng/mL) and a longer t½ (7.94 ± 3.01 vs. 6.16 ± 0.48 days). Mild to moderate adverse events occurred in the reference group (10 events in 4 subjects), while none were observed with AUL009.

Conclusion

AUL009 demonstrated delayed absorption, prolonged systemic exposure, and reduced peak concentration compared with once-weekly semaglutide, supporting its potential as a monthly semaglutide-loaded microsphere injectables with a favorable safety profile. Disclosure S. Kim: Employee; Current; AULBIO. C. Kim: Board Member; Current; AULBIO. T. An: Board Member; Current; AULBIO. A. Kim: Board Member; Current; AULBIO. J. Park: Employee; Current; AULBIO.

Zitieren

APA

KIM, S., KIM, C., AN, T., KIM, A., & PARK, J. (2026). 2837-LB: Pharmacokinetic and Safety Evaluation of AUL009, a Monthly Semaglutide-Loaded Microsphere Injectables Utilizing ExTenna Drug Delivery Technology in Healthy Male Subjects. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-2837-lb

Vancouver

KIM S, KIM C, AN T, KIM A, PARK J. 2837-LB: Pharmacokinetic and Safety Evaluation of AUL009, a Monthly Semaglutide-Loaded Microsphere Injectables Utilizing ExTenna Drug Delivery Technology in Healthy Male Subjects. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-2837-lb

BibTeX
@article{KIM2026,
  author = {KIM, SEOA and KIM, CHERNGJU and AN, TAEKUN and KIM, ARAM and PARK, JIWON},
  title = {2837-LB: Pharmacokinetic and Safety Evaluation of AUL009, a Monthly Semaglutide-Loaded Microsphere Injectables Utilizing ExTenna Drug Delivery Technology in Healthy Male Subjects},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {Supplement_1},
  doi = {10.2337/db26-2837-lb}
}
Kostenlos starten →